Latest Breaking News On - Sa noonan communications - Page 4 : comparemela.com

Autolus Therapeutics Announces Changes to its Board of Directors

LONDON, April 01, 2024 Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike.

United kingdomCity ofMike bonneyRavi raoOlivia manserOxford biomedicaJohnh johnsonRoche genentechSusana noonanJulia wilsonCambridge universityHarvard medical schoolExchange commissionGulf of maine research instituteDrug administrationImperial college london

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA)

LONDON, March 12, 2024 (GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP

United statesUnited kingdomCity ofSusana noonanOlivia manserDave brochuJulia wilsonExchange commission onSa noonan communicationsExchange commissionAutolu nucleusImportation authorisationChief technology officerOrphan drug designationOrphan medical product designationRegenerative medicine advanced therapy

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomSusana noonanJulia wilsonOlivia manserSa noonan communicationsThursday march

Autolus Therapeutics announces publication in Nature Communications

LONDON, Feb. 22, 2024 Autolus Therapeutics plc , a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces a publication in Nature.

City ofUnited kingdomLauren williamsJulia wilsonSusana noonanOlivia manserNature communicationsExchange commission onExchange commissionSa noonan communicationsStructure guided engineeringAutolus therapeuticsPrivate securities litigation reform actAutolu annual reportAutolu quarterly report

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG s NucleoCapture and HemoNucleoCapture Devices

/PRNewswire/ Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening.

City ofUnited kingdomJames frakesSusan noonanSantersu nucleocaptureAethlon hemopurifierScott maguireJim frakesSecurities exchangeExchange commissionCompany contactAethlon medical incSa noonan communicationsDrug administrationPrnewswire aethlon medical incCompany annual report on form